Navigation Links
AlphaRx Presents Company Overview and New Product Candidates at the Rodman Renshaw Healthcare Conference
Date:9/14/2009

MARKHAM, ON, Sept. 14 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB: ALRX). Speaking at the 11th Annual Rodman Renshaw Healthcare Conference in New York City, AlphaRx Director Dr. David Milroy presented a company overview focusing on the Company's product pipeline, nano drug delivery platform and the significant developments anticipated within the next 12 months. In Summary, AlphaRx will have 3-4 products in different stages of clinical development by the end of 2010, which have major market indications and opportunities, producing a portfolio of short to long term drug candidates to position the company for stable and sustainable growth. In addition, AlphaRx presented 2 new product candidates ARX1088 and ARX2038 which are being developed for herpes and lipid management respectively. These products have excellent safety profile and have over 25 years of successful clinical applications outside the US. AlphaRx is developing a new dosage form for ARX1088 and ARX2038 and planning to initiate Phase II clinical trails in the later part of 2010.

About ARX1088

The active ingredient in ARX1088 is an orally active interferon inducer. It primarily acts as an inducer of type I, alpha or beta interferon. In humans, these interferon levels double as early as four hours after administration of the drug. After 12-24 hours the levels can be one hundred or even several thousand fold higher, with maximum level achieved at 48 hours. It is a drug that is currently approved to treat certain anti-viral indications outside USA. ARX1088 is being developed as a topical treatment for herpes Simplex 1 and 2, as the mechanism of action is not directed at killing the virus, but through boosting the host's own immune system.

About ARX2038

The active ingredient in ARX2038 is a synthetic compound with a combination of unique properties. It demonstrates, heart, neuroprotective and cholesterol lowering properties.

It has extremely low toxicity (no signs of toxicity at 10,000 mg/kg) and produces no teratogenic, mutagenic or carcinogenic effects. Allergic reactions are extremely rare.

This compound significantly decreases cholesterol levels by up to 36%, LDL by 20%, triglycerides by 13% and elevates HDL by 47%. ARX2038 is a unique extended release formulation of this compound.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ALPHARx to Present at Rodman Renshaw Annual Global Investment Conference
2. AlphaRx Concludes GAI-122 Formulation Development Intended For The Prevention of Delirium
3. AlphaRx Receives China Patent on Its Drug Delivery Platform
4. AlphaRx and Venturepharm Announce Collaboration Agreement
5. AlphaRx Presents Positive Preclinical Data on Zysolin(TM) Inhalable Nanoparticles at Controlled Release Society Annual Meeting
6. AlphaRx Unveils its China Strategy
7. AlphaRx Reports Positive Preclinical Data on GAI-122 Against Liver Disease
8. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
9. AlphaRx Shareholder Update
10. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
11. AlphaRx Signs Cooperative Research and Development Agreement with US Army
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Mirror ... fall event , Look Awesome This Autumn with CoolSculpting®. Scheduled for Thursday, September ... refreshments. , Mirror Mirror Beauty Boutique is Houston’s largest CoolSculpting ...
(Date:9/20/2017)... NJ (PRWEB) , ... September 20, 2017 , ... ... a variety of settings, gather for the National Athletic Trainers’ Association Annual Clinical ... and case studies presented. It is also when Athletic Trainers are acknowledged by ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... Americans at risk of price gouging for their prescription drugs, according to a ... “Because Medicare isn’t negotiating on our behalf, there’s no consistency in drug pricing ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the ... in an average life. This mouse sets out on a journey that will show ... Mouseson” is the creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has ...
(Date:9/20/2017)... ... ... “The Financial Favor of God; Second Edition”: a personal and exquisite recipe for financial ... published author, Brooks Rathell. , “We typically hear about the favor of God. I ... of God. Not only does it exist, but it is meant for you. I ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... ... to Washington DC ... September 12 th – Monday, September 18 th .The Brain Tumor ... brain scans to the public.Where:  BTF,s Mobile MRI ... K Street NW, Washington, D.C.What:BTF brings its nationwide initiative, the Road to ...
(Date:9/7/2017)... Sept. 7, 2017  For nearly two decades, New Life Agency has ... Reproduction Insurance industry. Today, New Life Agency announces a powerful three-way partnership ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/7/2017)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ), ... cell and tissue hypothermic storage and cryopreservation ... President and CEO, will be presenting at two investment conferences ... 19 th Annual Global Investment Conference on Tuesday, September ... The conference is being held at the New York Palace ...
Breaking Medicine Technology: